A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

April 7, 2027

Study Completion Date

February 9, 2028

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

CC-99282

Specified dose on specified days

DRUG

Rituximab

Specified dose on specified days

DRUG

Obinutuzumab

Specified dose on specified days

DRUG

Tafasitamab

Specified dose on specified days

DRUG

Valemetostat

Specified dose on specified days

Trial Locations (66)

1090

Local Institution - 703, Vienna

1629

Local Institution - 254, Pilar

2100

Local Institution - 601, Copenhagen

3000

Local Institution - 902, Leuven

3100

Local Institution - 704, Sankt Pölten

5020

Local Institution - 701, Salzburg

7100

Local Institution - 603, Vejle

8200

Local Institution - 602, Aarhus

20162

Local Institution - 503, Milan

24127

Local Institution - 501, Bergamo

27100

Local Institution - 506, Pavia

28040

Local Institution - 302, Madrid

28046

Local Institution - 304, Madrid

29010

Local Institution - 303, Málaga

31200

Local Institution - 408, Toulouse

32207

Local Institution - 102, Tampa

32224

Local Institution - 111, Jacksonville

33076

Local Institution - 407, Bordeaux

34295

Local Institution - 409, Montpellier

37007

Local Institution - 305, Salamanca

40138

Local Institution - 504, Bologna

47392

Local Institution - 553, Busan

49100

Local Institution - 151, Petah Tikva

52621

Local Institution - 152, Ramat Gan

55905

Local Institution - 107, Rochester

59037

Local Institution - 406, Lille

63110

Local Institution - 104, St Louis

66210

Local Institution - 108, Overland Park

69495

Local Institution - 402, Pierre-Bénite

75010

Local Institution - 405, Paris

76038

Local Institution - 404, Rouen

77030

Local Institution - 101, Houston

80131

Local Institution - 502, Napoli

85259

Local Institution - 109, Scottsdale

91120

Local Institution - 150, Jerusalem

94010

Local Institution - 403, Créteil

94805

Local Institution - 401, Villejuif

100020

Local Institution - 653, Beijing

110001

Local Institution - 662, Shenyang

110022

Local Institution - 663, Shenyang

200025

Local Institution - 650, Shanghai

300060

Local Institution - 651, Tianjin

430079

Local Institution - 660, Wuhan

450000

Local Institution - 655, Zhengzhou

510060

Local Institution - 659, Guangzhou

510080

Local Institution - 657, Guangzhou

1246000

Local Institution - 452, São Paulo

7500921

Local Institution - 353, Santiago

7560908

Local Institution - 350, Santiago

7580206

Local Institution - 354, Santiago

8320000

Local Institution - 352, Santiago

07601

Local Institution - 103, Hackensack

C1118AAT

Local Institution - 255, Ciudad Autonoma de Buenos Aires

C1431FWO

Local Institution - 253, Buenos Aires

90610-000

Local Institution - 453, Porto Alegre

05651-901

Local Institution - 450, São Paulo

01401-002

Local Institution - 451, São Paulo

M5G 2M9

Local Institution - 201, Toronto

842 0383

Local Institution - 355, Recoleta

03080

Local Institution - 551, Seoul

06351

Local Institution - 550, Seoul

06591

Local Institution - 552, Seoul

08916

Local Institution - 306, Badalona (Barcelona)

08035

Local Institution - 301, Barcelona

EH4 2XU

Local Institution - 802, Edinburgh Scotland

SO01 6YD

Local Institution - 803, Southhampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY